Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Here are some examples of GLP-1 agonists: Dulaglutide (marketed as Trulicity) Exenatide (marketed as Byetta and Bydureon) Liraglutide (marketed as Victoza) Lixisenatide (marketed as Adlyxin) Semaglutide (marketed as Ozempic and Rybelsus) Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis: The Glucagon-like Peptide-1 (GLP-1) Agonists Market size is estimated at USD 11.87 billion in 2023, and is expected to reach USD 12.55 billion by 2028, growing at a CAGR of 1.12% during the forecast period (2023-2028)
This practice diverts a finite supply of a critical medicine away from its intended patient population of individuals with type two diabetes, for whom it is a vital tool for managing a serious chronic disease and preventing life threatening complications
Coupled with provider pressure to simply lose the weight in order to solve concerns such as diabetes and heart disease, factors such as insulin resistance, menopause, metabolic disorders, inflammation, and hunger/satiety hormone imbalance (often due to chronic dieting) are all but ignored, and responsibility is placed solely on the patient
The medication is usually started at a low dose (0.25 mg weekly for Ozempic, 0.25 mg for Wegovy) and titrated upward every four weeks to minimize gastrointestinal side effects
